טוען...
Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
Diabetes management during Ramadan fasting is challenging to the physician in terms of minimizing the risk of hypoglycemia. As compared to oral hypoglycemic agents (OHAs) and sulfonylureas (SUs), which carry a higher and significant risk of hypoglycemia, newer antidiabetic agents such as dipeptidyl...
שמור ב:
| הוצא לאור ב: | Diabetes Metab Syndr Obes |
|---|---|
| מחבר ראשי: | |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4404947/ https://ncbi.nlm.nih.gov/pubmed/25931826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S54683 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|